A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection

Transplantation

Volumn 62, Issue 5, 1996, Pages 594-599

  Woodle, E Steve ^a   Thistlethwaite, J Richard ^a   Gordon, John H ^b   Laskow, David ^c   Deierhoi, Mark H ^c   Burdick, James ^d   Pirsch, John D ^e   Sollinger, H ^e   Vincenti, Flavio ^f   Burrows, Lewis ^g   Schwartz, Beth ^g   Danovitch, Gabriel M ^h   Wilkinson, Alan H ^h   Shaffer, David ⁱ   Simpson, Mary Ann ⁱ   Freeman, Richard B ^j   Rohrer, Richard J ^j   Mendez, Robert ^k   Aswad, Saleh ^k   Munn, Stephen R ^l   Wiesner, Russell H ^l   Delmonico, Frank L ^m   Neylan, John ⁿ   Whelchel, John ⁿ   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MOUNT SINAI HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j TUFTS MEDICAL CENTER   (United States)

^k St Vincent's Hospital   (United States)

^l MAYO CLINIC   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; TACROLIMUS;

ADULT; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHRECTOMY; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0345691613     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00009     Document Type: Article

References (25)

1. Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP. Reexposure to OKT3 in renal allograft recipients. Transplantation 1988; 45: 349.
2. Norman DJ, Shield CF, Henell KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46: 523.
3. First ME, Schroeder TJ, Burtubise PE, et al. Successful retreatment of allograft rejection with OKT3. Transplantation 1989; 47: 88.
4. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136.
5. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283.
6. United States Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
7. European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
8. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation under FK506. JAMA 1990; 264: 63.
9. Shapiro R, Jordan M, Fung JJ, et al. Kidney transplantation under FK506 immunosuppression. Transplant Proc 1991; 23: 920.
10. Shapiro R, Jordan M, Scantlebury V, et al. FK506 in clinical kidney transplantation. Transplantation 1991; 23: 3065.
11. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of an early phase II study. Transplant Proc 1991; 23: 3071.
12. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of a late phase II study. Transplant Proc 1993; 25: 649.
13. Shapiro R, Jordan M, Scantlebury V, et al. A prospective, randomized trial of FK506 in renal transplantation: a comparison between double- and triple-drug therapy. Clin Transplant 1994; 8: 508.
14. United States Multicenter FK506 Liver Study Group. Use of FK506 as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679.
15. United States Multicenter FK506 Liver Study Group. Prognostic factors for successful conversion from cyclosporine to FK506-based immunosuppressive therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 641.
16. United States Multicenter FK506 Liver Study Group. Use of FK506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. Transplant Proc 1993; 25: 635.
17. Rucay P, Samuel D, Gillet D, Bismuth H. FK506 rescue therapy for refractory acute rejection in five liver recipients. Transplant Proc 1991; 23: 3000.
18. Shaw BW, Marlan R, Stratta R, Langnas A, Donovan J, Sorrell M. FK506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc 1991; 23: 294.
19. Woodle ES, Perdrizet GA, So SKS, White HM, Marsh JW. FK506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. Clin Transplant 1995; 9: 24.
20. Jordan M, Shapiro R, Vitas CA, et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860.
21. Armitage JM, Kormos RE, Fung JJ, et al. Preliminary experiences with FK506 in thoracic transplantation. Transplantation 1991; 52: 164.
22. Fung JJ, Todo S, Jain A, et al. Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990; 22: 6.
23. Woodle ES, Josephson M, Newell KA, et al. FK506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant (in press).
24. Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP. Reexposure to OKT3 in renal allograft recipients. Transplantation 1988; 45: 349.
25. Norman DJ, Shield CF, Henell KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46: 523.